-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Novocure announced that the U.S. FDA approved the company's NovoTTF-100L system to market, in conjunction with permeycere and platinum chemotherapy, first-line treatment can not be removed local late, or metastatic malignant thoracic mesothelioma (MPM). NovoTTF-100L is a non-invasive, silky cancer therapy that uses an electric field to treat tumor areas. Notably, NovoTTF-100L is the first FDA-approved new treatment for MPM in 15 years.
MPM is a rare form of cancer caused by asbestos exposure. Before the FDA approved NovoTTF-100L, the combination of permeitus and cisplatin was the only approved treatment for MPM, which cannot be removed.
NovoTTF-100L is a system that applies an electric field to the tumor treatment at the tumor site. Tumor therapy electric field is a low-intensity alternating electric field, which can affect the movement of specific cellular components in the process of fission division, disrupting fissional division. Because of the unique shape and characteristics of tumor cells when they are silky, it can disrupt the division of tumor cells in a targeted manner by regulating the alternating frequency of the electric field of tumor therapy. The system has been approved by the FDA for the treatment of glioblastoma.
.
